Spring Webinar – Annemieke Aarstma-Rus
Preclinical research for Duchenne muscular dystrophy: How does it work and why does it take so long?
In this webinar Annemieke Aartsma-Rus explains how drug development processes work, with a focus on preclinical research. She explains about the tools and the methods used and she also illustrates how to use them in the right way and what can happen when the research is not done properly with examples from the Duchenne field. Finally, she explains one therapeutic approach that is currently in the preclinical research phase: genome editing.
Please see the recording of her webinar here
Action Duchenne would like to thank the following sponsors who have provided financial support for this project but have no involvement in this project: HM Government (in partnership with the National Lottery Community Fund), Pfizer, PTC Therapeutics, Roche, GWF, Sarepta Therapeutics and all the individuals who made their contributions to make this project happen.
